Comparison of Pharmacokinetics, Bioequivalence, and Safety of Femorix® (Valenta Pharm Company, Russia) and Aubagio® (Sanofi Winthrop Industrie, France) Film-Coated Tablets (14 mg)

Autor:	A. V. Belostotskii, V. S. Arnautov, I. G. Lopukhov, E. V. Torshina, D. V. Reikhart, A. A. Globenko
Rok vydání:	2018
Předmět:	Pharmacology Traditional medicine Chemistry Pharmacology toxicology Cmax Bioequivalence Coated tablets 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Drug Discovery Healthy volunteers 030212 general & internal medicine 030217 neurology & neurosurgery Sanofi Winthrop
Zdroj:	Pharmaceutical Chemistry Journal. 51:954-959
ISSN:	1573-9031 0091-150X
DOI:	10.1007/s11094-018-1722-8
Popis:	The pharmacokinetics, bioequivalence, and safety of Femorix® (Valenta Pharm Co., Russia) and Aubagio® (SanofiWinthrop Industrie, France) film-coated tablets (14 mg) were compared in a double-blind randomized investigation in parallel groups of healthy volunteers. The bioavailabilities of Femorix® film-coated tablets (14 mg, Valenta Pharm Co., Russia) were 96.18% [87.92 – 105.22%] for ln(Cmax) and 96.24% [88.67 – 104.44%] for ln(AUC0–72) of those for Aubagio® film-coated tablets (14 mg, Sanofi Winthrop Industrie, France), which fell in the commonly accepted range (80 – 125%) for proving the bioequivalence of the tested products.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9495e7bb9e90ecf12982f179990984bd https://doi.org/10.1007/s11094-018-1722-8 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.